Jafron Biomedical Co Debt/EBITDA
The Total Debt to EBITDA Ratio of Jafron Biomedical Co (300529.SZ) as of Oct 16, 2026 is 1.60. In the previous year, Total Debt to EBITDA Ratio was 1.07 — a change of 49.21% (higher).
Get this data via API
Financial Data API
Debt/EBITDA
1.60
YoY
49.21%
Last updated:
The Jafron Biomedical Co Debt/EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | Debt/EBITDA | YoY |
|---|---|---|
| 1.60 | +49.21% | |
| 1.07 | -61.10% | |
| 2.76 | +131.17% | |
| 1.19 | +88.28% | |
| 0.63 | +2,144.47% | |
| 0.03 | -67.18% | |
| 0.09 | -60.98% | |
| 0.22 | -45.75% | |
| 0.41 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Jafron Biomedical Co Stock analysis
Frequently Asked Questions about Jafron Biomedical Co stock
Total Debt to EBITDA Ratio of Jafron Biomedical Co is 1.60 in 2025.
Total Debt to EBITDA Ratio of Jafron Biomedical Co changed from 1.07 to 1.60, representing a 49.21% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.
Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Leverage — Jafron Biomedical Co
All Key Metrics — Jafron Biomedical Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth